Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats
Authors:
- Fu-Ping ChenFCFu-Ping Chen
- Wayne M SullenderWSWayne M Sullender
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Prevention of respiratory syncytial virus infections in high‐risk infantsby monoclonal antibody (palivizumab)Pediatrics International, 2002
- Phase 1 Evaluation of the Respiratory Syncytial Virus–Specific Monoclonal Antibody Palivizumab in Recipients of Hematopoietic Stem Cell TransplantsThe Journal of Infectious Diseases, 2001
- Monoclonal Antibody-Resistant Mutants Selected with a Respiratory Syncytial Virus-Neutralizing Human Antibody Fab Fragment (Fab 19) Define a Unique Epitope on the Fusion (F) GlycoproteinVirology, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Vaccine-induced escape mutant of hepatitis B virusThe Lancet, 1990
- Respiratory Syncytial Viral Infection in Children with Compromised Immune FunctionNew England Journal of Medicine, 1986
- Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus.Proceedings of the National Academy of Sciences, 1984
- Respiratory syncytial virus infections in infants: Quantitation and duration of sheddingThe Journal of Pediatrics, 1976
- Isolation of variants during passage of a strain of foot-and-mouth disease virus in partly immunized cattleEpidemiology and Infection, 1965
- ANTIGENIC VARIANTS OF INFLUENZA A VIRUS (PR8 STRAIN)Journal of Experimental Medicine, 1958